IL135457A0 - Extended release formulation - Google Patents

Extended release formulation

Info

Publication number
IL135457A0
IL135457A0 IL13545798A IL13545798A IL135457A0 IL 135457 A0 IL135457 A0 IL 135457A0 IL 13545798 A IL13545798 A IL 13545798A IL 13545798 A IL13545798 A IL 13545798A IL 135457 A0 IL135457 A0 IL 135457A0
Authority
IL
Israel
Prior art keywords
release formulation
extended release
formulation
extended
release
Prior art date
Application number
IL13545798A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL135457(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL135457A0 publication Critical patent/IL135457A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13545798A 1997-11-05 1998-11-03 Extended release formulation IL135457A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05
PCT/US1998/023338 WO1999022724A2 (en) 1997-11-05 1998-11-03 Extended release formulation containing venlafaxin

Publications (1)

Publication Number Publication Date
IL135457A0 true IL135457A0 (en) 2001-05-20

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13545798A IL135457A0 (en) 1997-11-05 1998-11-03 Extended release formulation

Country Status (39)

Country Link
EP (1) EP1028718B1 (pt)
JP (1) JP2001521892A (pt)
KR (1) KR20010031797A (pt)
CN (1) CN1278165A (pt)
AR (1) AR014012A1 (pt)
AT (1) ATE237320T1 (pt)
AU (1) AU747978B2 (pt)
BG (1) BG104397A (pt)
BR (1) BR9813179A (pt)
CA (1) CA2305242A1 (pt)
CL (1) CL2004001705A1 (pt)
CO (1) CO5011060A1 (pt)
CZ (1) CZ20001659A3 (pt)
DE (1) DE69813602T2 (pt)
DK (1) DK1028718T3 (pt)
EA (1) EA200000487A1 (pt)
EE (1) EE04577B1 (pt)
ES (1) ES2196620T3 (pt)
GE (1) GEP20043198B (pt)
HK (1) HK1029056A1 (pt)
HR (1) HRP20000213B1 (pt)
HU (1) HU225238B1 (pt)
ID (1) ID26317A (pt)
IL (1) IL135457A0 (pt)
MA (1) MA24691A1 (pt)
NO (1) NO20002126L (pt)
NZ (1) NZ504460A (pt)
PA (1) PA8462501A1 (pt)
PE (1) PE128699A1 (pt)
PL (1) PL341141A1 (pt)
PT (1) PT1028718E (pt)
SK (1) SK6472000A3 (pt)
SV (1) SV1998000131A (pt)
TR (1) TR200001232T2 (pt)
TW (1) TW555568B (pt)
UA (1) UA77145C2 (pt)
UY (2) UY25234A1 (pt)
WO (1) WO1999022724A2 (pt)
ZA (1) ZA9810081B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039132D1 (de) * 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
WO2003050075A1 (en) * 2001-12-05 2003-06-19 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
AU2002247945A1 (en) * 2001-12-13 2003-06-23 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
EP1474123A1 (en) * 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Controlled release pharmaceutical formulation containing venlafaxine
AR039163A1 (es) 2002-03-28 2005-02-09 Synthon Bv Besilato de venlafaxina
AR039165A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Venlafaxina base
WO2003082805A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
SI1502587T1 (sl) * 2003-07-30 2007-02-28 Pharmathen Sa Formulacija z zadrzevanim sproscanjem za Venlafaxin hidroklorid
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
PL1711169T3 (pl) 2004-02-04 2007-10-31 Alembic Ltd Powlekane tabletki chlorowodorku wenlafaksyny o wydłużonym czasie uwalniania
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
ES2196620T3 (es) 2003-12-16
AR014012A1 (es) 2001-01-31
ID26317A (id) 2000-12-14
DE69813602D1 (de) 2003-05-22
HUP0004287A3 (en) 2002-05-28
HRP20000213B1 (en) 2004-04-30
SV1998000131A (es) 1999-11-18
CZ20001659A3 (cs) 2001-10-17
PE128699A1 (es) 2000-01-06
TR200001232T2 (tr) 2000-12-21
NO20002126D0 (no) 2000-04-26
BR9813179A (pt) 2000-08-22
PT1028718E (pt) 2003-07-31
HK1029056A1 (en) 2001-03-23
WO1999022724A3 (en) 1999-07-22
EP1028718A2 (en) 2000-08-23
ZA9810081B (en) 2000-05-04
NZ504460A (en) 2003-01-31
EE04577B1 (et) 2006-02-15
EP1028718B1 (en) 2003-04-16
WO1999022724A2 (en) 1999-05-14
PA8462501A1 (es) 2000-05-24
PL341141A1 (en) 2001-03-26
DE69813602T2 (de) 2003-11-06
UY25692A1 (es) 2000-03-31
JP2001521892A (ja) 2001-11-13
DK1028718T3 (da) 2003-07-28
ATE237320T1 (de) 2003-05-15
EE200000212A (et) 2001-04-16
TW555568B (en) 2003-10-01
CN1278165A (zh) 2000-12-27
CA2305242A1 (en) 1999-05-14
HRP20000213A2 (en) 2000-12-31
BG104397A (en) 2001-02-28
GEP20043198B (en) 2004-03-25
EA200000487A1 (ru) 2000-10-30
UA77145C2 (en) 2006-11-15
SK6472000A3 (en) 2000-11-07
CO5011060A1 (es) 2001-02-28
HUP0004287A2 (hu) 2002-04-29
AU747978B2 (en) 2002-05-30
KR20010031797A (ko) 2001-04-16
MA24691A1 (fr) 1999-07-01
HU225238B1 (en) 2006-08-28
NO20002126L (no) 2000-05-04
UY25234A1 (es) 2000-12-29
CL2004001705A1 (es) 2005-06-03
AU1300399A (en) 1999-05-24

Similar Documents

Publication Publication Date Title
EG24198A (en) Extended release formulation
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
IL143496A0 (en) Controlled release formulation comprising gnrh-ii
GB9715751D0 (en) Formulations
SG71879A1 (en) Controlled release compositions
ZA9510687B (en) Sustained release caffeine formulation
EP1030654A4 (en) PREPARATION OF OMEPRAZOLE
ZA9811461B (en) New formulation
HRP20000213B1 (en) Extended release formulation
SG71789A1 (en) Controlled release compositions
GB2310860B (en) Stable release agents
ZA985669B (en) New formulation
GB9724544D0 (en) Novel Formulation
ZA9810710B (en) Sustained release formulations comprising alpha-glucosidase-inhibitors
EP0968655A4 (en) SPREAD
GB2322867B (en) Release agent
ZA9810773B (en) Revitalisation formulation
GB9706957D0 (en) Formulation
GB9915929D0 (en) Novel release latch-c-i-p
GB9711946D0 (en) Release devices
GB2342044B (en) Quick release compositions
GB9725275D0 (en) Formulation
GB9721807D0 (en) Formulation
HU0400312D0 (en) Extended release formulation containing venlaflaxine hydrochloride
SI1028718T1 (en) Extended release formulation containing venlafaxin